These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

603 related items for PubMed ID: 14980106

  • 1. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
    Wu XR, Wang Q, Shi SS, Lu MH, Guo WD.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
    [Abstract] [Full Text] [Related]

  • 2. [The plasma levels of transforming growth factor beta1 and the protein expressions of alpha-SMA, urokinase plasminogen activator and plasminogen activator inhibitor-1 in liver of patients with different grades of hepatic fibrosis].
    Wu XR, Lv MH, Wang Q, Shi SS, Guo WD.
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):400-2. PubMed ID: 15268802
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
    Zhou H, Wu X, Lu X, Chen G, Ye X, Huang J.
    Thromb Res; 2009 Jul; 123(3):537-42. PubMed ID: 18691743
    [Abstract] [Full Text] [Related]

  • 4. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brünner N, Sweep CG, Duffy MJ.
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [Abstract] [Full Text] [Related]

  • 5. [Expression of urokinase-type plasminogen activator and its receptor in plasma of patients with cerebral infarction].
    Song SJ, Hu JB, Wang HX, Wen SQ, Ding MP, Huang JZ.
    Zhonghua Yi Xue Za Zhi; 2003 Sep 25; 83(18):1583-5. PubMed ID: 14642114
    [Abstract] [Full Text] [Related]

  • 6. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep 25; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

  • 7. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M, Masanobu M, Takehiko K, Shoko T, Akira F, Katsushige A, Takashi H, Yoshiyuki O, Shigeru K.
    J Lab Clin Med; 2004 Aug 25; 144(2):69-77. PubMed ID: 15322501
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 25; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
    Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, Schirren J, Ebert W, Fiehn W, Luther T, Magdolen V, Schmitt M, Harbeck N.
    Anticancer Res; 2004 Feb 01; 24(6):4147-61. PubMed ID: 15736466
    [Abstract] [Full Text] [Related]

  • 15. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
    Pavey SJ, Marsh NA, Ray MJ, Butler D, Dare AJ, Hawson GA.
    Boll Soc Ital Biol Sper; 1996 Feb 01; 72(11-12):331-40. PubMed ID: 9178585
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA.
    Cancer Res; 2004 Jul 01; 64(13):4563-8. PubMed ID: 15231667
    [Abstract] [Full Text] [Related]

  • 18. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 01; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 19. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
    Warnecke-Eberz U, Prenzel KL, Baldus SE, Metzger R, Dienes HP, Bollschweiler E, Hoelscher AH, Schneider PM.
    Pancreas; 2008 Mar 01; 36(2):173-7. PubMed ID: 18376309
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.